Ann: FY23 Result - Presentation, page-2

Highlights:

• Sales revenue up 19% to a record $1,956m (16% in CC).
• Cochlear implant units rose 16% to 44,156, fueled by market growth, clinical capacity, market share gains & COVID catch-up surgeries.
• Successful launch of Cochlear™ Nucleus® 8 Sound Processor in Q2 boosts demand.
• Adult referral rate improvement indicates success in awareness & access initiatives.
• Net profit at $301m, up 4% (7% in CC).
• Underlying net profit** up 10% at $305m, top end of guidance.Underlying profit margin (pre-cloud) at 17%.
• Final dividend rises 21% to $1.75/share; full year dividends at $3.30/share.
• $30m shares repurchased in ongoing buyback, aiming to reduce cash to ~$200m.
• FY24 profit guidance: $355-375m, marking 16-23% growth.
• Strong sales growth in developed markets: up 15%.
• Emerging markets surge nearly 20% with robust growth in countries like India & China.